{"ticker": {"uuid": "e7eab167-44af-4b3c-9289-1559e792bd4a", "symbol": "NVCR", "name": "Novocure Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NVCR Reinstated by JP Morgan -- Rating Remains Neutral", "summary": "JP Morgan has reinstated coverage on NovoCure (NVCR) with a price target of $17.00 and a Neutral rating. While GuruFocus's GF Value\u2122 suggests NVCR is modestly undervalued at $18.71, insider activity shows $0.9 million in shares sold recently, indicating a cautious outlook among i", "url": "https://www.gurufocus.com/news/8955172/nvcr-reinstated-by-jp-morgan-rating-remains-neutral", "source_name": "GuruFocus", "published_at": "2026-07-13T12:10:28", "published_display": "13 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Novocure(NVCR.US) With Hold Rating, Cuts Target Price to $17", "summary": "J.P. Morgan has maintained its Hold rating on Novocure (NVCR.US) but has reduced the target price for the stock from $23 to $17. This adjustment reflects a revised outlook from the analyst firm for Novocure.", "url": "https://www.moomoo.com/news/post/72855216/jp-morgan-maintains-novocure-nvcrus-with-hold-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-13T11:10:28", "published_display": "13 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes NovoCure stock coverage with neutral rating", "summary": "JPMorgan has reinstated coverage of NovoCure Ltd. (NASDAQ:NVCR) with a Neutral rating and a $17.00 price target for December 2027. The firm anticipates profitability by 2028, driven by new launches in pancreatic cancer and brain metastases. The company's valuation reflects its ma", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-resumes-novocure-stock-coverage-with-neutral-rating-93CH-4787590", "source_name": "Investing.com", "published_at": "2026-07-13T08:10:28", "published_display": "13 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOanYzaXpKd3g5bHBJYlhybG9aOWZKQzZfVUEtaXNRSUxjSlBzSTJnQTVIWUtmdE9JTVZONDdGa2ZTXzJFWEZnakRwaTlwLVFSNkRHR0lJM1h2MERDektpOXJCX0JnM0xlcF9BWDdfakJzdzl6NXFKNS1OUlV4SGh6VFNGeUQ3eG9TU1J3a0o5aWJzdVhMNHBhc3lhMURLUmlMXzF6MUR2dEhDZmljQ2ItVWxxR2gzU1lvWGlKR0QtbmUxQnRsQWRaMTE3MVF6OTBHSEh6TlVVM1F1eTUtczMwTEJfTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T23:19:51+00:00", "published_display": "12 Jul 2026 23:19", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NovoCure\u2019s Shift Into Russell Value Indexes Recast NVCR\u2019s Core Investment Narrative?", "summary": "NovoCure Limited (NasdaqGS: NVCR) was recently included in several Russell value indexes in late June 2026, categorizing it as a value-oriented medical technology company. While this inclusion offers increased visibility, it doesn't fundamentally change the company's investment n", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/does-novocures-shift-into-russell-value-indexes-recast-nvcrs", "source_name": "Simply Wall Street", "published_at": "2026-07-10T20:10:28", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026 (NASDAQ:NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNS3UxNUVZOWFLUUV4M1MwWEV5c19WOGhMdTFDREhMaVpPSHRHUWdBZmZSN2pfWTIxV3lqUHBjdElTTnBPVUp2WU1PdGRWWjFqb1FCR1Z6SEhRV0dpN1VxOGZjZTl2NGktS19fYm9XTERBR2Zfd1R6RGtJVVY4eXd3X0ZkRlJnenRiVWpkOEY2VzdwRXM2RlB1TWFqd1A1dFkyaWlBZjFn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T19:01:54+00:00", "published_display": "10 Jul 2026 19:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNRUZzYUdSTnlZZ0Vib3B1YUotVFFvcl9ld1o4TG5YVVVXa1lhYXNiZy1Rdk5ra3NDeDA4cUt4MTVVam93MlpFUUp6MFBWTUhsUXdIemplT2IzbE1DNVh1eV9RYkN4dTdFdWVCM0d4UkQxVUlnWEJFOGNGczlOOU9xV1ZCZXd3WE9zeGpnZlNUOGpQdDIyZnRBM0hRMjBkWlNWUW9GVGQ4V1B0LUdQYmNZNDNHM01aeXdhalJDdVNiVEJyZHJudGh4Z3cwVHFPWGlHWDBrdXhpLUVuWENpTGpyMndGWkNQcm9vV2Uzck1QbGM?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-09T21:40:00+00:00", "published_display": "09 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NovoCure Ltd. \u2013 FWB:038", "summary": "This article provides the \"Price to book forward\" value for NovoCure Ltd. (FWB:038). It indicates that the period value for this metric is 0, with no change or percentage change data available. The information is presented within a financial market data context on TradingView.", "url": "https://www.tradingview.com/symbols/FWB-038/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:12:50", "published_display": "09 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR stock. NovoCure\u2019s business case stays in view.", "summary": "This article discusses NovoCure Ltd. (NVCR), a cancer care company known for its tumor treating fields platform, including its flagship product Optune. It highlights the company's business model, particularly its focus on recurring adoption, reimbursement, and physician familiari", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/nvcr-stock-novocure-s-business-case-stays-in-view/69715324", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:13:31", "published_display": "07 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation?", "summary": "NovoCure (NVCR) is under scrutiny after a legal investigation following its Phase 3 TRIDENT trial results caused a significant stock drop, despite recent short-term gains. Currently, the stock is considered 34% undervalued with a fair value of $26.07 against its last close of $17", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/is-novocure-nvcr-cheap-as-trident-fallout-clouds-its-valuati", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:40:24", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure\u2019s Optune Pax\u00ae Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer", "summary": "Novocure announced that its Optune Pax\u00ae device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer, in conjunction with gemcitabine and nab-paclitaxel. This approval is based on results from the Phase 3 PANOVA-3 trial, which showed a ", "url": "https://finance.yahoo.com/healthcare/articles/novocure-optune-pax-receives-ce-110000694.html", "source_name": "Market source", "published_at": "2026-07-04T07:09:41", "published_display": "04 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase", "summary": "NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 1,905 ordinary shares through the company's 2025 Employee Share Purchase Plan on June 30, 2026. The shares were purchased at a discounted price of $11.15 each, representing 85% of the closing price on Janua", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-479470f132d5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T16:39:58", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure's Cancer Treatment Device Option Pax Gets European Approval", "summary": "NovoCure Limited has received CE mark approval for its portable medical device, Option Pax, to treat locally advanced pancreatic cancer in Europe. This treatment, used concomitantly with gemcitabine and nab-paclitaxel, had previously received FDA approval and will be launched in ", "url": "https://finance.yahoo.com/healthcare/articles/novocures-cancer-treatment-device-option-170000553.html", "source_name": "Market source", "published_at": "2026-07-02T10:00:00", "published_display": "02 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure to Report Second Quarter 2026 Financial Results", "summary": "Novocure (NASDAQ: NVCR) is set to announce its financial results for the second quarter of 2026 on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure, a glo", "url": "https://finance.yahoo.com/healthcare/articles/novocure-report-second-quarter-2026-110000052.html", "source_name": "Market source", "published_at": "2026-07-02T06:10:23", "published_display": "02 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings", "summary": "NovoCure Ltd's General Counsel, Ben Arye Barak, acquired 1,299 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) for the period of January 1, 2026, through June 30, 2026. The shares were purchased at a reported price of $11.15 each, bringing his direc", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-060032da4c57.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:40:39", "published_display": "02 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan", "summary": "NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) at $11.15 per share. This routine, compensation-related transaction, exempt under Rule 16b-3(c), increased Danziger's direct holdings to 416,742 ordinar", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-9a4ff10a3a95.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:23", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan", "summary": "NovoCure's CEO, Leonard Frank X, acquired 1,905 ordinary shares at $11.15 each through the company's 2025 Employee Share Purchase Plan for the first half of 2026. This transaction is exempt under Rule 16b-3(c) and increases his direct holdings to 461,425 ordinary shares. The purc", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-d3dd394eb073.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:23", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure sets July 23 call for Q2 2026 results before markets open", "summary": "Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure is an oncology company s", "url": "https://www.stocktitan.net/news/NVCR/novocure-to-report-second-quarter-2026-financial-22puo8jqpdqi.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:36", "published_display": "01 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR - NovoCure Ltd Volatility & Greeks", "summary": "This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and inst", "url": "https://finviz.com/stock?t=NVCR&ty=ocv&ta=2&p=w&ov=list_strike&s=26", "source_name": "Finviz", "published_at": "2026-07-01T04:09:23", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure receives CE Mark for pancreatic cancer device in Europe", "summary": "Novocure's Optune Pax device has received CE Mark approval in Europe for treating locally advanced pancreatic cancer when used with chemotherapy. This approval is based on Phase 3 trial results showing improved overall survival and time to pain progression for patients using Optu", "url": "https://www.investing.com/news/company-news/novocure-receives-ce-mark-for-pancreatic-cancer-device-in-europe-93CH-4767487", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:30", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure wins CE Mark for Optune Pax pancreatic cancer treatment", "summary": "Novocure's Optune Pax device has received CE Mark approval for treating locally advanced pancreatic cancer in Europe, following prior U.S. approval. The approval is based on Phase 3 PANOVA-3 trial results showing a 2-month median overall survival benefit and improved quality of l", "url": "https://grafa.com/en/news/united-states/novocure-optune-pax-ce-mark-pancreatic-cancer", "source_name": "grafa.com", "published_at": "2026-06-30T11:20:00", "published_display": "30 Jun 2026 11:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe", "summary": "Novocure's wearable medical device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in Europe. This approval is based on data from the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in overall survival and de", "url": "https://www.stocktitan.net/news/NVCR/novocure-s-optune-pax-receives-ce-mark-for-the-treatment-of-locally-1esnjd5uqz9x.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:45", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach", "summary": "Novocure's wearable device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in adults when used with gemcitabine and nab-paclitaxel. This approval is supported by positive Phase 3 PANOVA-3 trial data, which showed significant improvements", "url": "https://www.stocktitan.net/sec-filings/NVCR/8-k-novo-cure-ltd-reports-material-event-176705ff78f7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:44", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start", "summary": "NovoCure's stock rose 8.1% after its Phase 3 TRIDENT trial revealed no significant survival benefit from starting Tumor Treating Fields (TTFields) earlier for glioblastoma patients. The results indicate that the timing of TTFields initiation, rather than the therapy's feasibility", "url": "https://www.sahmcapital.com/news/content/novocure-nvcr-is-up-81-after-trident-shows-no-survival-gain-from-earlier-ttfields-start-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T15:40:37", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh", "summary": "This article provides an overview of NovoCure Ltd. (N2VC34) stock, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics for both annual and quarterly periods", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-N2VC34/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T07:39:57", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results", "summary": "NovoCure (NVCR) is considered potentially 42% undervalued despite reporting mixed topline Phase 3 TRIDENT data for glioblastoma that showed no statistically significant overall survival benefit. The stock's current price of US$15.05 is a significant discount to its estimated fair", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-could-be-42-undervalued-on-mixed-trident-trial/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-26T06:10:40", "published_display": "26 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NovoCure Limited (NVCR) stock, based on analysis from several financial experts. It details the current stock price, historical performance, and analysts' maximum and minimum price estimates for the company. Additionally, the ", "url": "https://www.tradingview.com/symbols/NASDAQ-NVCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:30", "published_display": "26 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR)", "summary": "This article provides an overview of NovoCure Limited (NASDAQ: NVCR) stock, including current price, historical performance, analyst forecasts, and detailed financial data. It covers earnings, revenue, market capitalization, EBITDA, and upcoming earnings report dates. The article", "url": "https://www.tradingview.com/symbols/NASDAQ-NVCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:40", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Actuals & Estimates (LSX:A140ML)", "summary": "This article provides comprehensive financial data and analyst estimates for NovoCure Ltd. (A140ML) on the Lang & Schwarz Exchange. It covers the company's stock performance, market capitalization, earnings, revenue, and future price forecasts, alongside frequently asked question", "url": "https://www.tradingview.com/symbols/LSX-A140ML/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:12", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTldOUFB5UzRsMDc3Nk1GSWpYTVJjSlZKRk9QbGtfSDdYVFNUM19XdG5ncHNsOW9NSklCZ3oyZENhc2JZa3dCV0w4RXY1MWFIQzRiMUFRYkhHX096QzJ6TDloajg4ZUJ4amQ0VE8wV0xuQzNscWlFMlhfTXFwUi1rdzFTanlhOGQtc3Y3SnotVUhzM1dKS3ZWUUNKY2RoLW9yLXlkS0pDRWlzQ1FJQnNjdUppbmlBUnNjSnBXQ1plVXRmRzVOU05uWXpR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVm9Uc0FjT205V0FnZlczTnJJd015V2xWOWdYV0VYZDdfWEJhZHplYm1zZ0hCSW1NQTF3RDkzNm41elJ5c3FReFRBdWNSLWNxcDIxWlo5Wjk1ZElwdzZiME5reklMQVYzMTQ0SURHZ1RhQkNfcmo3Z2FnTzluOWVoV0VSRkRKV2lzOWY3Q1VSOFJJMEQ4N0ZVTTF2VTVuY3JncGJrQ3NuYTVDemtSQU9ydU92bG5pVlBfMXlnajkxa2JnZ1NxbTBvMTdLRQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure: Solid Fundamentals, But TRIDENT Caps Near-Term Upside (NASDAQ:NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWdxbHg3Ui04dElNWjFNZENrZ3h0cUtXSFpPbUVYUU1wRkkybHBLM1ViZmVWYy1rSVAyV3VUcVF6XzFzQUlIN3Z4VExSZjh4aFU1ME51ZHhibXBnQUNoeFNyX0Q2dG10WWtYN0hUTzNVdVIzQm1fVmc3Rk93T1FrRFlKTmcwdnlsMVlrN2V3a2c5akZpQ3Y1Xzh3WFVBNEZHaE1PVHFPZUliQXlw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZVROODdxZjFGT2NtcTl4XzF3VndicEZXZXFLeGdnUkVrdHlZYi1vS2hqMjdQRHNRaEZXRHdBd0VmYkpVOTg1alFwVjFidHduZzZuRlQzaHNXM1VSbWppZWdxMmlOLWpXLUxwVzlEdjZQOHp0RVU4WDdnOXU4WVdUQjZ6V0RkeS1aQmFFOXVXOC01ZGFoaDdGRA?oc=5", "source_name": "Market source", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/c1e92cc4-11ce-3768-84f9-abad49696f0f/amgen-vs.-novocure%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-06-19T17:10:34+00:00", "published_display": "19 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer", "summary": "", "url": "https://finance.yahoo.com/m/2c4be6b6-e951-3aa0-8940-9a2f7d6e860a/novocure-tumbles-after.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T20:05:42+00:00", "published_display": "18 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUUFjN3VyODNxeXpIbVBYQnYyQUFVcFJteGRfS1laV3VtNkpvUC1OSkZiMGhaQ2FEd01aT05OcG9lZlhHZERnbWwtNXZqS3oyeU82ZnpwWUE1RUlLSkhSa2V0YWd0TFpMSXJ2Z1NFbGd5Y196Ymx5SEVsOEd1aVREamJYVjBIUUdJOVFsWXRrWWV4SGJJNHIxY1ROQ3JoZEFBTjlydlhEYXZ4UjM4ZzlaaHp3cDRlUjJ6S0FDSHExOUY?oc=5", "source_name": "Sahm", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure's glioblastoma trial shows survival data, but no primary win", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNGROdkRNQWg5emRGOUxIdXY4MHV3MkFvOXM2ZzFLeE9JeXM4d0NiUXVsQndERUl1dy1aYmhaRVNOTDhaRjZQeU11ZUw3SURfbGQ4SmNVSTE2X29mTnNrNXB5V2U1a1laeHc2MmlWY2ZnM09lSDYyak9iRXZJS09iWFNMZWpUWmpuc3pwd0JiNVZlUjRsa2I2bHZwM04wTVctM1FYcTlaNUVMejlkNzlNelRmTlZFd2ZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NVCR) Sees Significant Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOaUFQYnFCdDdiOXlmUVByTzZxVk85WmRuWHE0eUxpZ29rRmwyLUFoYWx4UG5xZm16UXJOVHBmanc5bHBWRXhXZ1p0WEZhRnlBaVIzRWR2R08tdjlYclZxaWJaaTExX2Q2R3pRWHBjMHlGa3Q1eW9PYU1fdFRETndDUE1oMnFnVGxGX3hOWTZCakNXZ2ZITG84?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NVCR) Experiences Significant Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPYVZXOU9EN3ZzSFN3R1UwUmdsN3JPOHhXU3dzNzZnX3FIaDB0MWZfMFRrVXhIaVdvUElrUmVBRi1XVVlMWUFxODdmVnN2TWw4V3NnMHBpWWxBRnVpckFMajZjSGd3cmE0LUlGUnp0WlNGYURXQjhsVkdJMnVFVmJDWlpfLWZVUDJMYkNUS3ZEdENJcVY2aTRLMWJvZ1dhTHBNY3VGYjFkTHdNZWlzLW9sSQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNYldKeFJqMDlUd0NPVno4eXdXMDhkTUVleENWWUVFczh0ajVLNWJQTWI3c19ON1BTV2p1WjFNZTdUc3RfZlZndUtLYjJKMHZhRG1JVnUzeDk1Qm9YTDhmTjNLR0hXdWpFSF9renNlRFFuU045Rjg3Y3daY195M3AtTkJVTFdsMW5FNWxyNTJPdkFYZVczOTZqRk9QY1ZNYVdRZzF6Nw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure stock falls on late-stage trial setback (NVCR:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOd3RGb01SUkQwZjI2OUZEQUtVUlNnaVlqX2YxTF9CMzJMdUhMT2NXemNHOEY3Tk5BZEVZV1M1ZlF4dXh1eV9tNDlpT2FmMTdySnVXYXpxMGhPeUE2amdLd3hld2FCemVBd2oxUy1ScFJobHZQd0dRR3lLUGZUa1hYdlVlcHdLOXhRVW1V?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNVXlrQkJQSnQwS1UxMVQySTNmMXdRaDJwbS01dlg0a1lSMjR1MzhkdUN1cllEVlVGaTdKeHZmaDRVVUVBbUxTU0FJZ2owZC15QTE3M19NUjVBRFR3VTFZdlo4NlhoX1BWZDJBUmQwWVlPc2FScmg2bEtiUVVjTS1sZTlZd3lndjhHcXB4SWRPVklZdDhtS3RJTWQzcmRiLXF4a1RydThyYU0tQkJQOE9mQUNrQkZ2eXVvTHltWFhKeWtvOHpMQ1ZCbdIBzgFBVV95cUxQYmQ0ak1wZ0RIWTEyY0xpaFhXQXhFeVRBTldpcExpajFzOURvSUlyREU3WTZXQjhzU2FOc1RPX29KRTNxQ1pKNnZtS2k2REFFZmd5cFlrZ2JKVDBMWTdERGNCTmhJanprZzlKRHc2WFdtMFBVaG1tOTJsUFVFT3o2c0QwM3FsTWpxS2haZlk0ZWFOZHY2Y2d3djJaSTZJSVpVU1pBQ0l6NlMtV0NTOXFGazRrTFI3bWRXVlZpck9ZSGd1eHBIcUdZQWxsQzZoQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Frank Leonard\u2019s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcW9kWHVkcnB6TnNqRXlIQy15QnE5Y25ZVVAwSWtZVUJwTFpDR2MxU0RsUWR6bG94R1p5NVlvNUVkUW8xeTFqbDY0OHpQekNDaTFldkplRnNBazZGeU5tbzhoVVY5UkVrcG9TT0ZFam00MzllWWhoWERaeFJtbHdDdkRxT3Z2Mm9yWHdqNjBHcTZNOHVkUXBzeFRoTVc5c1VuX1JHWWQwWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold NovoCure Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPOGU2cWxyLXhNM2NoTHluUmlUU180emFxSjUtdERrdEN4LWxxRWVTbWxUTmc4QVFqb2t4c0FyUWNuOFB6Y1RDQ3hPaEpxcm9ubkU4ZE9fOGVib2dYQVFUcXdwV09vanVzanNlQzRYNmFiZGxHSmJ3TzJrejdvVXVpM01qMGlBNXpiWjEyRzBhams5Q1lobFpBWmhld0lodU1MZ3J2VUlHaHQxdTRRbm1BYTE5a0dYQ3dTN2ZNSV9DYVoxMmMtQmp4TdIBzgFBVV95cUxPV05pUUtieEFzcFdZQ3ZiSnBZaGNQaGVhYWNJVTRIeXFCZm81V3N3TWdlRTl4eTNabWRxT2lGcjZzRkIyaEhSdTcyS202YlFfMlhlM3ppUnZzYi1iSUtiakZWX1NtS3dOM1ZrMWFnMDd1MVhaNGsxMjdhdUljcXdQNWZINzZWZmM2Tm9RdDUwTmptWlVzWUhOaGQ1UEhZTmgxWU56V2ZXZkJvS2wtblNnNWI5UEFxZ05HM2Z1X2hLMzZqN21wM3B2aDcxam9sQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNN1huNnRwak9wc3FreWQ4RV9EV2d1NklYRFFidXRlN0E3eDBiQnBWOEc4UXBSTjNPcWRRM3Z1c1pHQkVvZENBeFhJSVJuRncycWhIN2dKZHc4Ql9DNHBUdmdTWGtyajluQ0s2LVFDWHNBLVQweEZvNVVWN2FnaENkbTFVRFpRN21DTGJIV0xTR3VTSkJveU83Y05SUGJXelluSmc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQeTNXOXdRVTBkcmdIaXhaaUQ1SXhLa25WeFo2cHRWNC1OSjduNFFqZ1BZMXByemxzemhNWmx2dTg2NV9FOGR5ckhQVEJKUUZ3N3ZNb0V4elR5bDV0cXhNUUUxT0xuMHJhODhRcG5KcllSVU9UV095SHlkZTYzWUplY3hrN1BfRGIyQjRWV0xQTzZJczE1UVRDbnZn?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Francis Leonard sells 9,734 NVCR shares, $133K proceeds (NASDAQ: NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQbFI2TUprNFFvOTRjcUZMaHJla0M5WW5PTW12QmE1Wm5lYmZzRWxueGlvek9YV09hN1JZRFRLTEtRZzNDZE9OUFBUcHVkN3UzOTl1cEdCX2pBTm9uSTNuakFxM1NuX1ZxbGVXWDc4a21PSTZLbXBGbElsUmkxTm0yLUU5OGxhdEtjc0dxUUhRSVlzbFJm?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NVCR Reinstated by JP Morgan -- Rating Remains Neutral", "summary": "JP Morgan has reinstated coverage on NovoCure (NVCR) with a price target of $17.00 and a Neutral rating. While GuruFocus's GF Value\u2122 suggests NVCR is modestly undervalued at $18.71, insider activity shows $0.9 million in shares sold recently, indicating a cautious outlook among i", "url": "https://www.gurufocus.com/news/8955172/nvcr-reinstated-by-jp-morgan-rating-remains-neutral", "source_name": "GuruFocus", "published_at": "2026-07-13T12:10:28", "published_display": "13 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Novocure(NVCR.US) With Hold Rating, Cuts Target Price to $17", "summary": "J.P. Morgan has maintained its Hold rating on Novocure (NVCR.US) but has reduced the target price for the stock from $23 to $17. This adjustment reflects a revised outlook from the analyst firm for Novocure.", "url": "https://www.moomoo.com/news/post/72855216/jp-morgan-maintains-novocure-nvcrus-with-hold-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-13T11:10:28", "published_display": "13 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes NovoCure stock coverage with neutral rating", "summary": "JPMorgan has reinstated coverage of NovoCure Ltd. (NASDAQ:NVCR) with a Neutral rating and a $17.00 price target for December 2027. The firm anticipates profitability by 2028, driven by new launches in pancreatic cancer and brain metastases. The company's valuation reflects its ma", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-resumes-novocure-stock-coverage-with-neutral-rating-93CH-4787590", "source_name": "Investing.com", "published_at": "2026-07-13T08:10:28", "published_display": "13 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOanYzaXpKd3g5bHBJYlhybG9aOWZKQzZfVUEtaXNRSUxjSlBzSTJnQTVIWUtmdE9JTVZONDdGa2ZTXzJFWEZnakRwaTlwLVFSNkRHR0lJM1h2MERDektpOXJCX0JnM0xlcF9BWDdfakJzdzl6NXFKNS1OUlV4SGh6VFNGeUQ3eG9TU1J3a0o5aWJzdVhMNHBhc3lhMURLUmlMXzF6MUR2dEhDZmljQ2ItVWxxR2gzU1lvWGlKR0QtbmUxQnRsQWRaMTE3MVF6OTBHSEh6TlVVM1F1eTUtczMwTEJfTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T23:19:51+00:00", "published_display": "12 Jul 2026 23:19", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NovoCure\u2019s Shift Into Russell Value Indexes Recast NVCR\u2019s Core Investment Narrative?", "summary": "NovoCure Limited (NasdaqGS: NVCR) was recently included in several Russell value indexes in late June 2026, categorizing it as a value-oriented medical technology company. While this inclusion offers increased visibility, it doesn't fundamentally change the company's investment n", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/does-novocures-shift-into-russell-value-indexes-recast-nvcrs", "source_name": "Simply Wall Street", "published_at": "2026-07-10T20:10:28", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026 (NASDAQ:NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNS3UxNUVZOWFLUUV4M1MwWEV5c19WOGhMdTFDREhMaVpPSHRHUWdBZmZSN2pfWTIxV3lqUHBjdElTTnBPVUp2WU1PdGRWWjFqb1FCR1Z6SEhRV0dpN1VxOGZjZTl2NGktS19fYm9XTERBR2Zfd1R6RGtJVVY4eXd3X0ZkRlJnenRiVWpkOEY2VzdwRXM2RlB1TWFqd1A1dFkyaWlBZjFn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T19:01:54+00:00", "published_display": "10 Jul 2026 19:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNRUZzYUdSTnlZZ0Vib3B1YUotVFFvcl9ld1o4TG5YVVVXa1lhYXNiZy1Rdk5ra3NDeDA4cUt4MTVVam93MlpFUUp6MFBWTUhsUXdIemplT2IzbE1DNVh1eV9RYkN4dTdFdWVCM0d4UkQxVUlnWEJFOGNGczlOOU9xV1ZCZXd3WE9zeGpnZlNUOGpQdDIyZnRBM0hRMjBkWlNWUW9GVGQ4V1B0LUdQYmNZNDNHM01aeXdhalJDdVNiVEJyZHJudGh4Z3cwVHFPWGlHWDBrdXhpLUVuWENpTGpyMndGWkNQcm9vV2Uzck1QbGM?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-09T21:40:00+00:00", "published_display": "09 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NovoCure Ltd. \u2013 FWB:038", "summary": "This article provides the \"Price to book forward\" value for NovoCure Ltd. (FWB:038). It indicates that the period value for this metric is 0, with no change or percentage change data available. The information is presented within a financial market data context on TradingView.", "url": "https://www.tradingview.com/symbols/FWB-038/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:12:50", "published_display": "09 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR stock. NovoCure\u2019s business case stays in view.", "summary": "This article discusses NovoCure Ltd. (NVCR), a cancer care company known for its tumor treating fields platform, including its flagship product Optune. It highlights the company's business model, particularly its focus on recurring adoption, reimbursement, and physician familiari", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/nvcr-stock-novocure-s-business-case-stays-in-view/69715324", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:13:31", "published_display": "07 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation?", "summary": "NovoCure (NVCR) is under scrutiny after a legal investigation following its Phase 3 TRIDENT trial results caused a significant stock drop, despite recent short-term gains. Currently, the stock is considered 34% undervalued with a fair value of $26.07 against its last close of $17", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/is-novocure-nvcr-cheap-as-trident-fallout-clouds-its-valuati", "source_name": "Simply Wall Street", "published_at": "2026-07-06T18:40:24", "published_display": "06 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure\u2019s Optune Pax\u00ae Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer", "summary": "Novocure announced that its Optune Pax\u00ae device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer, in conjunction with gemcitabine and nab-paclitaxel. This approval is based on results from the Phase 3 PANOVA-3 trial, which showed a ", "url": "https://finance.yahoo.com/healthcare/articles/novocure-optune-pax-receives-ce-110000694.html", "source_name": "Market source", "published_at": "2026-07-04T07:09:41", "published_display": "04 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase", "summary": "NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 1,905 ordinary shares through the company's 2025 Employee Share Purchase Plan on June 30, 2026. The shares were purchased at a discounted price of $11.15 each, representing 85% of the closing price on Janua", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-479470f132d5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T16:39:58", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure's Cancer Treatment Device Option Pax Gets European Approval", "summary": "NovoCure Limited has received CE mark approval for its portable medical device, Option Pax, to treat locally advanced pancreatic cancer in Europe. This treatment, used concomitantly with gemcitabine and nab-paclitaxel, had previously received FDA approval and will be launched in ", "url": "https://finance.yahoo.com/healthcare/articles/novocures-cancer-treatment-device-option-170000553.html", "source_name": "Market source", "published_at": "2026-07-02T10:00:00", "published_display": "02 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure to Report Second Quarter 2026 Financial Results", "summary": "Novocure (NASDAQ: NVCR) is set to announce its financial results for the second quarter of 2026 on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure, a glo", "url": "https://finance.yahoo.com/healthcare/articles/novocure-report-second-quarter-2026-110000052.html", "source_name": "Market source", "published_at": "2026-07-02T06:10:23", "published_display": "02 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings", "summary": "NovoCure Ltd's General Counsel, Ben Arye Barak, acquired 1,299 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) for the period of January 1, 2026, through June 30, 2026. The shares were purchased at a reported price of $11.15 each, bringing his direc", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-060032da4c57.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:40:39", "published_display": "02 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan", "summary": "NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) at $11.15 per share. This routine, compensation-related transaction, exempt under Rule 16b-3(c), increased Danziger's direct holdings to 416,742 ordinar", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-9a4ff10a3a95.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:23", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan", "summary": "NovoCure's CEO, Leonard Frank X, acquired 1,905 ordinary shares at $11.15 each through the company's 2025 Employee Share Purchase Plan for the first half of 2026. This transaction is exempt under Rule 16b-3(c) and increases his direct holdings to 461,425 ordinary shares. The purc", "url": "https://www.stocktitan.net/sec-filings/NVCR/form-4-novo-cure-ltd-insider-trading-activity-d3dd394eb073.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:23", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure sets July 23 call for Q2 2026 results before markets open", "summary": "Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure is an oncology company s", "url": "https://www.stocktitan.net/news/NVCR/novocure-to-report-second-quarter-2026-financial-22puo8jqpdqi.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:36", "published_display": "01 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR - NovoCure Ltd Volatility & Greeks", "summary": "This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and inst", "url": "https://finviz.com/stock?t=NVCR&ty=ocv&ta=2&p=w&ov=list_strike&s=26", "source_name": "Finviz", "published_at": "2026-07-01T04:09:23", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure receives CE Mark for pancreatic cancer device in Europe", "summary": "Novocure's Optune Pax device has received CE Mark approval in Europe for treating locally advanced pancreatic cancer when used with chemotherapy. This approval is based on Phase 3 trial results showing improved overall survival and time to pain progression for patients using Optu", "url": "https://www.investing.com/news/company-news/novocure-receives-ce-mark-for-pancreatic-cancer-device-in-europe-93CH-4767487", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:30", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure wins CE Mark for Optune Pax pancreatic cancer treatment", "summary": "Novocure's Optune Pax device has received CE Mark approval for treating locally advanced pancreatic cancer in Europe, following prior U.S. approval. The approval is based on Phase 3 PANOVA-3 trial results showing a 2-month median overall survival benefit and improved quality of l", "url": "https://grafa.com/en/news/united-states/novocure-optune-pax-ce-mark-pancreatic-cancer", "source_name": "grafa.com", "published_at": "2026-06-30T11:20:00", "published_display": "30 Jun 2026 11:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe", "summary": "Novocure's wearable medical device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in Europe. This approval is based on data from the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in overall survival and de", "url": "https://www.stocktitan.net/news/NVCR/novocure-s-optune-pax-receives-ce-mark-for-the-treatment-of-locally-1esnjd5uqz9x.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:45", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach", "summary": "Novocure's wearable device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in adults when used with gemcitabine and nab-paclitaxel. This approval is supported by positive Phase 3 PANOVA-3 trial data, which showed significant improvements", "url": "https://www.stocktitan.net/sec-filings/NVCR/8-k-novo-cure-ltd-reports-material-event-176705ff78f7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:10:44", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start", "summary": "NovoCure's stock rose 8.1% after its Phase 3 TRIDENT trial revealed no significant survival benefit from starting Tumor Treating Fields (TTFields) earlier for glioblastoma patients. The results indicate that the timing of TTFields initiation, rather than the therapy's feasibility", "url": "https://www.sahmcapital.com/news/content/novocure-nvcr-is-up-81-after-trident-shows-no-survival-gain-from-earlier-ttfields-start-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T15:40:37", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh", "summary": "This article provides an overview of NovoCure Ltd. (N2VC34) stock, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics for both annual and quarterly periods", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-N2VC34/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T07:39:57", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results", "summary": "NovoCure (NVCR) is considered potentially 42% undervalued despite reporting mixed topline Phase 3 TRIDENT data for glioblastoma that showed no statistically significant overall survival benefit. The stock's current price of US$15.05 is a significant discount to its estimated fair", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-could-be-42-undervalued-on-mixed-trident-trial/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-26T06:10:40", "published_display": "26 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NVCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NovoCure Limited (NVCR) stock, based on analysis from several financial experts. It details the current stock price, historical performance, and analysts' maximum and minimum price estimates for the company. Additionally, the ", "url": "https://www.tradingview.com/symbols/NASDAQ-NVCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:30", "published_display": "26 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR)", "summary": "This article provides an overview of NovoCure Limited (NASDAQ: NVCR) stock, including current price, historical performance, analyst forecasts, and detailed financial data. It covers earnings, revenue, market capitalization, EBITDA, and upcoming earnings report dates. The article", "url": "https://www.tradingview.com/symbols/NASDAQ-NVCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:40", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure Ltd. Actuals & Estimates (LSX:A140ML)", "summary": "This article provides comprehensive financial data and analyst estimates for NovoCure Ltd. (A140ML) on the Lang & Schwarz Exchange. It covers the company's stock performance, market capitalization, earnings, revenue, and future price forecasts, alongside frequently asked question", "url": "https://www.tradingview.com/symbols/LSX-A140ML/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:12", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTldOUFB5UzRsMDc3Nk1GSWpYTVJjSlZKRk9QbGtfSDdYVFNUM19XdG5ncHNsOW9NSklCZ3oyZENhc2JZa3dCV0w4RXY1MWFIQzRiMUFRYkhHX096QzJ6TDloajg4ZUJ4amQ0VE8wV0xuQzNscWlFMlhfTXFwUi1rdzFTanlhOGQtc3Y3SnotVUhzM1dKS3ZWUUNKY2RoLW9yLXlkS0pDRWlzQ1FJQnNjdUppbmlBUnNjSnBXQ1plVXRmRzVOU05uWXpR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVm9Uc0FjT205V0FnZlczTnJJd015V2xWOWdYV0VYZDdfWEJhZHplYm1zZ0hCSW1NQTF3RDkzNm41elJ5c3FReFRBdWNSLWNxcDIxWlo5Wjk1ZElwdzZiME5reklMQVYzMTQ0SURHZ1RhQkNfcmo3Z2FnTzluOWVoV0VSRkRKV2lzOWY3Q1VSOFJJMEQ4N0ZVTTF2VTVuY3JncGJrQ3NuYTVDemtSQU9ydU92bG5pVlBfMXlnajkxa2JnZ1NxbTBvMTdLRQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure: Solid Fundamentals, But TRIDENT Caps Near-Term Upside (NASDAQ:NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWdxbHg3Ui04dElNWjFNZENrZ3h0cUtXSFpPbUVYUU1wRkkybHBLM1ViZmVWYy1rSVAyV3VUcVF6XzFzQUlIN3Z4VExSZjh4aFU1ME51ZHhibXBnQUNoeFNyX0Q2dG10WWtYN0hUTzNVdVIzQm1fVmc3Rk93T1FrRFlKTmcwdnlsMVlrN2V3a2c5akZpQ3Y1Xzh3WFVBNEZHaE1PVHFPZUliQXlw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZVROODdxZjFGT2NtcTl4XzF3VndicEZXZXFLeGdnUkVrdHlZYi1vS2hqMjdQRHNRaEZXRHdBd0VmYkpVOTg1alFwVjFidHduZzZuRlQzaHNXM1VSbWppZWdxMmlOLWpXLUxwVzlEdjZQOHp0RVU4WDdnOXU4WVdUQjZ6V0RkeS1aQmFFOXVXOC01ZGFoaDdGRA?oc=5", "source_name": "Market source", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/c1e92cc4-11ce-3768-84f9-abad49696f0f/amgen-vs.-novocure%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-06-19T17:10:34+00:00", "published_display": "19 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer", "summary": "", "url": "https://finance.yahoo.com/m/2c4be6b6-e951-3aa0-8940-9a2f7d6e860a/novocure-tumbles-after.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T20:05:42+00:00", "published_display": "18 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUUFjN3VyODNxeXpIbVBYQnYyQUFVcFJteGRfS1laV3VtNkpvUC1OSkZiMGhaQ2FEd01aT05OcG9lZlhHZERnbWwtNXZqS3oyeU82ZnpwWUE1RUlLSkhSa2V0YWd0TFpMSXJ2Z1NFbGd5Y196Ymx5SEVsOEd1aVREamJYVjBIUUdJOVFsWXRrWWV4SGJJNHIxY1ROQ3JoZEFBTjlydlhEYXZ4UjM4ZzlaaHp3cDRlUjJ6S0FDSHExOUY?oc=5", "source_name": "Sahm", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure's glioblastoma trial shows survival data, but no primary win", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNGROdkRNQWg5emRGOUxIdXY4MHV3MkFvOXM2ZzFLeE9JeXM4d0NiUXVsQndERUl1dy1aYmhaRVNOTDhaRjZQeU11ZUw3SURfbGQ4SmNVSTE2X29mTnNrNXB5V2U1a1laeHc2MmlWY2ZnM09lSDYyak9iRXZJS09iWFNMZWpUWmpuc3pwd0JiNVZlUjRsa2I2bHZwM04wTVctM1FYcTlaNUVMejlkNzlNelRmTlZFd2ZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NVCR) Sees Significant Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOaUFQYnFCdDdiOXlmUVByTzZxVk85WmRuWHE0eUxpZ29rRmwyLUFoYWx4UG5xZm16UXJOVHBmanc5bHBWRXhXZ1p0WEZhRnlBaVIzRWR2R08tdjlYclZxaWJaaTExX2Q2R3pRWHBjMHlGa3Q1eW9PYU1fdFRETndDUE1oMnFnVGxGX3hOWTZCakNXZ2ZITG84?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NVCR) Experiences Significant Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPYVZXOU9EN3ZzSFN3R1UwUmdsN3JPOHhXU3dzNzZnX3FIaDB0MWZfMFRrVXhIaVdvUElrUmVBRi1XVVlMWUFxODdmVnN2TWw4V3NnMHBpWWxBRnVpckFMajZjSGd3cmE0LUlGUnp0WlNGYURXQjhsVkdJMnVFVmJDWlpfLWZVUDJMYkNUS3ZEdENJcVY2aTRLMWJvZ1dhTHBNY3VGYjFkTHdNZWlzLW9sSQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNYldKeFJqMDlUd0NPVno4eXdXMDhkTUVleENWWUVFczh0ajVLNWJQTWI3c19ON1BTV2p1WjFNZTdUc3RfZlZndUtLYjJKMHZhRG1JVnUzeDk1Qm9YTDhmTjNLR0hXdWpFSF9renNlRFFuU045Rjg3Y3daY195M3AtTkJVTFdsMW5FNWxyNTJPdkFYZVczOTZqRk9QY1ZNYVdRZzF6Nw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novocure stock falls on late-stage trial setback (NVCR:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOd3RGb01SUkQwZjI2OUZEQUtVUlNnaVlqX2YxTF9CMzJMdUhMT2NXemNHOEY3Tk5BZEVZV1M1ZlF4dXh1eV9tNDlpT2FmMTdySnVXYXpxMGhPeUE2amdLd3hld2FCemVBd2oxUy1ScFJobHZQd0dRR3lLUGZUa1hYdlVlcHdLOXhRVW1V?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Frank Leonard\u2019s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcW9kWHVkcnB6TnNqRXlIQy15QnE5Y25ZVVAwSWtZVUJwTFpDR2MxU0RsUWR6bG94R1p5NVlvNUVkUW8xeTFqbDY0OHpQekNDaTFldkplRnNBazZGeU5tbzhoVVY5UkVrcG9TT0ZFam00MzllWWhoWERaeFJtbHdDdkRxT3Z2Mm9yWHdqNjBHcTZNOHVkUXBzeFRoTVc5c1VuX1JHWWQwWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold NovoCure Shares Recently?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure (NVCR) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNN1huNnRwak9wc3FreWQ4RV9EV2d1NklYRFFidXRlN0E3eDBiQnBWOEc4UXBSTjNPcWRRM3Z1c1pHQkVvZENBeFhJSVJuRncycWhIN2dKZHc4Ql9DNHBUdmdTWGtyajluQ0s2LVFDWHNBLVQweEZvNVVWN2FnaENkbTFVRFpRN21DTGJIV0xTR3VTSkJveU83Y05SUGJXelluSmc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQeTNXOXdRVTBkcmdIaXhaaUQ1SXhLa25WeFo2cHRWNC1OSjduNFFqZ1BZMXByemxzemhNWmx2dTg2NV9FOGR5ckhQVEJKUUZ3N3ZNb0V4elR5bDV0cXhNUUUxT0xuMHJhODhRcG5KcllSVU9UV095SHlkZTYzWUplY3hrN1BfRGIyQjRWV0xQTzZJczE1UVRDbnZn?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francis Leonard sells 9,734 NVCR shares, $133K proceeds (NASDAQ: NVCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQbFI2TUprNFFvOTRjcUZMaHJla0M5WW5PTW12QmE1Wm5lYmZzRWxueGlvek9YV09hN1JZRFRLTEtRZzNDZE9OUFBUcHVkN3UzOTl1cEdCX2pBTm9uSTNuakFxM1NuX1ZxbGVXWDc4a21PSTZLbXBGbElsUmkxTm0yLUU5OGxhdEtjc0dxUUhRSVlzbFJm?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 64, "sentiment_summary": {"positive": 14, "negative": 7, "neutral": 43, "score": 53, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.55, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 11.69, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}], "positive_events": 14, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 16.3, "latest_week": "2026-07-10", "one_week_move": -5.2, "four_week_move": -8.3, "twelve_week_move": 27.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.576281, "market_dynamics_buy_signal": false, "relative_strength": 4.989329, "fair_value_gap": -4.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 42.7723, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.2% over one week, -8.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "GuruFocus", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "The Motley Fool", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 24}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.2% over one week, -8.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "NVCR Reinstated by JP Morgan -- Rating Remains Neutral"}], "updated_at": "2026-07-16T05:12:49.697259+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}